Salvia, salvinorins and salvanorin derivatives
See all (180)
Chavkin et al. (2004). Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. The Journal of Pharmacology and Experimental Therapeutics.
Pichini et al. (2005). Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Communications in Mass Spectrometry.
Zhang et al. (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors. Psychopharmacology.
Ansonoff et al. (2006). Antinociceptive and hypothermic effects of salvinorin a are abolished in a novel strain of κ-opioid receptor-1 knockout mice. The Journal of Pharmacology and Experimental Therapeutics.
Capasso et al. (2006). The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterology and Motility.
Harding et al. (2006). Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. Journal of Natural Products.
Butelman et al. (2007). Effects of salvinorin a, a κ-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ-receptor homology to humans. The Journal of Pharmacology and Experimental Therapeutic.
Vortherms et al. (2007). Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor. The Journal of Biological Chemistry.
Capasso et al. (2008). Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. British Journal of Pharmacology.
McDonough et al. (2008). The detection and quantitative analysis of the psychoactive component of Salvia divinorum, salvinorin A, in human biological fluids using liquid chromatography-mass spectrometry. Journal of Analytical Toxicology.
Butelman et al. (2009). Unconditioned behavioral effects of the powerful k-opioid hallucinogen Salvinorin A in nonhuman primates: Fast onset and entry into cerebrospinal fluid. The Journal of Pharmacology and Experimental Therapeutics.
Kennedy & Wiseman. Direct analysis of Salvia divinorum leaves for salvinorin A by thin layer chromatography and desorption electrospray ionization multi-stage tandem mass spectrometry. Rapid Communications in Mass Spectrometry.
Barnes & Snow (2012). Analysis of Salvinorin A in plants, water, and urine using solid-phase microextraction-comprehensive two-dimensional gas chromatography-time of flight mass spectrometry. Journal of Chromatography.
Butelman et al. (2012). Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. The Journal of Pharmacology and Experimental Therapeutics.
Willard, McGuffin & Smith (2012). Forensic analysis of Salvia divinorum using multivariate statistical procedures. Part I: discrimination from related Salvia species. Analytical and Bioanalytical Chemistry.
Willard, McGuffin & Smith (2012). Forensic analysis of Salvia divinorum using multivariate statistical procedures. Part II: association of adulterated samples to S. divinorum. Analytical and Bioanalytical Chemistry.
Dueweke (2013). Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: what are the clinical features of Salvia divinorum toxicity? Emergency Medicine Journal.
Gutierrez & Cooper (2014). Investigating correlates of synthetic marijuana and Salvia use in light and intermittent smokers and college students in a predominantly Hispanic sample. Experimental and Clinical Psychopharmacology.
Hamidpour et al. (2014). Chemistry, pharmacology, and medicinal property of sage (salvia) to prevent and cure illnesses such as obesity, diabetes, depression, dementia, lupus, autism, heart disease, and cancer. Journal of Traditional and Complementary Medicine.
Lin et al. (2014). Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan. Journal of Food and Drug Analysis.
Butelman & Kreek (2015). Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology.
Butelman & Kreek (2015). Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology.
Maqueda et al. (2015). Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. The International Journal of Neuropsychopharmacology.
Crowley et al. (2016). Synthetic studies of neoclerodane diterpenes from salvia divinorum: identification of a potent and centrally acting μ opioid analgesic with reduced abuse liability. Journal of Medicinal Chemistry.
Maqueda et al. (2016). Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-a in humans. The International Journal of Neuropsychopharmacology.